Engineered immune cells take on Hard-to-Treat ovarian cancer

NCT ID NCT06646627

Recruiting now Disease control Sponsor: Stanford University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new treatment called B7-H3 CAR T cells for adults with ovarian cancer that has come back and no longer responds to platinum chemotherapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize and attack cancer cells, and then infusing them back. The main goals are to see if the cells can be made successfully and to find the safest dose, with a secondary look at whether tumors shrink.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: B7-H3 CAR T cells (a type of immune cell therapy)
What this could lead to: If this works, it could point toward a new treatment option for ovarian cancer that has stopped responding to standard chemotherapy.
What could go wrong: This is a very early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. The therapy may not shrink tumors, and there are risks like severe immune reactions or side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Stanford University
RECRUITING

Palo Alto, California, 94304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.